-  Is currently participating in or has participated in a study of an investigational<br/>             agent or has used an investigational device within 4 weeks prior to randomization.<br/><br/>          -  Has had major surgery within 4 weeks prior to randomization or radiation therapy<br/>             within 2 weeks prior to randomization, or who has not recovered (i.e., ≤ Grade 1 or<br/>             at baseline) from AEs due to prior treatment.<br/><br/>          -  Has had prior treatment with any anti-programmed cell death (anti-PD-1), or<br/>             programmed cell death ligand 1 (PD-L1), or PD-L2 agent or an antibody targeting any<br/>             other immune-regulatory receptors or mechanisms.<br/><br/>          -  Has received prior therapy with vascular endothelial growth factor (VEGF)/VEGF<br/>             receptors (VEGFR) or mechanistic target of rapamycin (mTOR) targeting agents.<br/><br/>          -  Has a history of severe hypersensitivity reaction (e.g., generalized rash/erythema,<br/>             hypotension, bronchospasm, angioedema or anaphylaxis) to axitinib or sunitinib.<br/><br/>          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any<br/>             other form of immunosuppressive therapy within 7 days prior to randomization, except<br/>             in the case of central nervous system (CNS) metastases.<br/><br/>          -  Has an active autoimmune disease requiring systemic treatment with in the past 3<br/>             months or a documented history of clinically severe autoimmune disease, or a syndrome<br/>             that requires systemic or immunosuppressive agents. Note: Participants with vitiligo,<br/>             diabetes Type I, resolved childhood asthma/atopy, hypothyroidism stable on hormone<br/>             replacement, or Sjøgren's syndrome are not excluded.<br/><br/>          -  Has a known additional malignancy that has progressed or has required active<br/>             treatment in the last 3 years. Note: Participants with basal cell carcinoma of the<br/>             skin, squamous cell carcinoma of the skin that has undergone potentially curative<br/>             therapy or carcinoma in situ are not excluded.<br/><br/>          -  Has known active CNS metastases and/or carcinomatous meningitis.<br/><br/>          -  Has a history of (non-infectious) pneumonitis that required steroids or current<br/>             pneumonitis.<br/><br/>          -  Has an active infection requiring systemic therapy.<br/><br/>          -  Has a known history of Human Immunodeficiency Virus (HIV).<br/><br/>          -  Has known active Hepatitis B or Hepatitis C infection.<br/><br/>          -  Has received a live virus vaccine within 30 days of randomization.<br/><br/>          -  Has a clinically significant gastrointestinal (GI) abnormality including:<br/><br/>          -  Inability to take oral medication<br/><br/>          -  Requirement for intravenous alimentation<br/><br/>          -  Prior surgical procedures affecting absorption including total gastric resection<br/><br/>          -  Treatment for active peptic ulcer within the past 6 months<br/><br/>          -  Active GI bleeding, as evidenced by hematemesis, hematochezia or melena in the past 3<br/>             months without evidence of resolution documented by endoscopy or colonoscopy<br/><br/>          -  Intraluminal metastatic lesion with suspected bleeding, inflammatory bowel disease,<br/>             ulcerative colitis or other GI condition associated with increased risk of<br/>             perforation, or history of GI perforation<br/><br/>          -  Malabsorption syndromes<br/><br/>          -  Inflammatory bowel disease<br/><br/>          -  Has QT interval corrected for heart rate (QTc) ≥480 msec.<br/><br/>          -  Has a history of any of the following cardiovascular conditions within 12 months of<br/>             screening:<br/><br/>          -  Myocardial infarction<br/><br/>          -  Unstable angina pectoris<br/><br/>          -  Cardiac angioplasty or stenting<br/><br/>          -  Coronary/peripheral artery bypass graft<br/><br/>          -  Class III or IV congestive heart failure per New York Heart Association<br/><br/>          -  Cerebrovascular accident or transient ischemic attack<br/><br/>          -  Has a history of deep vein thrombosis or pulmonary embolism within 6 months of<br/>             screening.<br/><br/>          -  Has poorly controlled hypertension defined as systolic blood pressure (SBP) ≥150 mm<br/>             Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg.<br/><br/>          -  Has evidence of inadequate wound healing.<br/><br/>          -  Has active bleeding disorder or other history of significant bleeding episodes within<br/>             30 days of randomization.<br/><br/>          -  Has hemoptysis within 6 weeks prior to randomization.<br/><br/>          -  Has current use or anticipated need for treatment with drugs or foods that are known<br/>             strong cytochrome P450 (CYP3A4/5) inhibitors.<br/><br/>          -  Has current use or anticipated need for treatment with drugs that are known strong<br/>             CYP3A4/5 inducers, including but not limited to carbamazepine,<br/>             phenobarbital,phenytoin, rifabutin, rifampin, and St. John's wort.<br/><br/>          -  Has known psychiatric or substance abuse disorders that would interfere with<br/>             cooperation with the requirements of the study.<br/><br/>          -  Has had a prior solid organ transplant.<br/><br/>          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the<br/>             projected duration of the study, starting with the screening visit through 120 days<br/>             after the last dose of study drug.<br/><br/>          -  Is, at the time of signing informed consent, a known regular user (including<br/>             "recreational use") of any illicit drugs or had a recent history (within the last<br/>             year) of drug or alcohol abuse.<br/>